about
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementEnhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program.Subdural hematomas during CML therapy with imatinib mesylate.Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchyRosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation.An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases.Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia modelOverview of autologous stem cell transplantation.Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.Analysis of the microenvironment necessary for engraftment: role of the vascular smooth muscle-like stromal cells.Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressedChronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors.Acute promyelocytic leukemia: a case-based review.Depletion of bone marrow CCSP-expressing cells delays airway regeneration.Advances in targeted therapy for chronic myeloid leukemia.Effect of radiation and cell implantation on wound healing in a rat model.Uterine-derived stem cells reconstitute the bone marrow of irradiated mice.Group V phospholipase A2 in bone marrow-derived myeloid cells and bronchial epithelial cells promotes bacterial clearance after Escherichia coli pneumonia.Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.Hematopoiesis in the elderly.Human mesenchymal stromal cells improve scar thickness without enhancing cardiac function in a chronic ischaemic heart failure modelSecond-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapySecond autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant ReseOvercoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model.Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium.Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.Facing the NIH funding crisis: how professional societies can help.Cell therapy for age-related disorders: myocardial infarction and stroke--a mini-review.Cell-based therapies for osteonecrosis of the femoral head.Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.Is there a role for autotransplants in AML in first remission?Mesenchymal stromal cells as supportive cells for hepatocytes.
P50
Q27861120-0E68D8DD-38A2-45A2-BAC5-FF869C57FB8FQ28591605-2BBCE30E-4546-4B6B-84B2-0629EF4217C3Q30230287-835221D9-F372-4D5A-8983-85672ED27F95Q33362624-1CF0067A-9B9C-488B-B488-1AAA5AECCC2DQ33490119-B57CEB7D-7E26-49D8-8CFD-AF8DBE46C5B5Q33626182-264ADB36-8049-4E57-AFC7-98C8EF3BA5C9Q33637202-C6C7F609-F65C-4E64-B281-14410F4512EEQ33783282-3EE42BC6-6F21-4CBD-BDDD-5B90FE777676Q33815423-C22CC9FA-6194-4053-9E14-3245F8089C7CQ34038567-19AEA056-845B-4983-9464-C84C2BF1F295Q34049208-19150AE0-323C-4E79-B847-8D63983942CDQ34084193-F3D60CAD-F14B-4915-B1A5-BBA943251C7EQ34140706-C875DDFD-9D18-42B2-8297-28357FA09273Q34484052-BD3E392F-4E14-41EA-8AFA-B7326B88EB0AQ34528330-255CEA4C-4A45-417F-9309-E1BF8CE60FD8Q34567322-436EBBCA-6395-43C8-8822-85AFCD2D6419Q34818397-BC1111E7-DC18-47C3-8593-0CCBDA2BB640Q35127005-97B8A838-503C-4880-A4C3-208B543165C4Q35153100-818E381A-346E-45EA-85CA-C4D5AB74893AQ35160190-F1F020A7-5DAF-432C-B324-486FC36417E8Q35163144-57E8E432-983A-4157-8765-0942DE5D5756Q35323569-87EB7603-22BC-4773-A5E5-612D450EBDF6Q35372227-CEBC2CAE-CE16-4854-A875-CBC379B2C685Q35692054-0260CCDF-0C17-4D83-A2DC-1A3A77C60BD5Q35809433-BE10E278-36E2-48A2-ACB0-924632B66849Q35896781-5EEC415C-3535-492D-A1BA-CA19E68746B7Q35930635-6D9062D6-6629-40DA-A77B-4768C0B8D32EQ35964878-3C072EE9-3C0A-481B-9B2F-E81A5702BF34Q36094697-C21ABD6C-9BF8-4221-8ADC-B4E2E36FDD0AQ36248964-C57C876A-F7D4-49A2-869F-F5697D9CF258Q36984538-B97F0AAC-0992-4B66-9120-35AA11C8F70DQ37052853-0BB4F840-CB8A-472D-A97F-C8CA72B7B43CQ37073720-B678F18F-89D2-4E74-9D34-F4C55854AD65Q37085060-F16B5252-9B05-4F01-AB4B-FF79C4F1D8E2Q37089160-AE99E8E2-4930-43B9-A2C1-6C07B766D86AQ37271223-C82C996C-57F1-412C-A8D0-491445E16640Q37274092-867F8A7F-982C-4094-A5A7-733F1C256515Q37293519-F1D0DA25-5B7C-4205-8089-2CFE70349861Q37369377-5510575E-AD44-46FE-8AA5-42BC1B6AAFE4Q37544251-4C13C8C8-E90D-41EE-9E80-E4C99F3349AA
P50
description
researcher ORCID ID = 0000-0002-7676-6059
@en
wetenschapper
@nl
name
Armand Keating
@ast
Armand Keating
@en
Armand Keating
@es
Armand Keating
@nl
type
label
Armand Keating
@ast
Armand Keating
@en
Armand Keating
@es
Armand Keating
@nl
prefLabel
Armand Keating
@ast
Armand Keating
@en
Armand Keating
@es
Armand Keating
@nl
P31
P496
0000-0002-7676-6059